Shares of Insys Therapeutics were on the rise in Thursday’s trading session after the company announced that its epinephrine nasal spray was given fast track designation from the Food & Drug Administration. The FDA has given fast track designation to Insys Therapeutics’ epinephrine nasal spray as an investigational treatment for anaphylaxis, an acute, life-threatening allergic … Continue reading “Insys Therapeutics Skyrockets on FDA Fast Track Designation”
